"Prima now expects to be in a position to commence the first sales of CVacTM in DHCC in the near
future."
"The Company has a licensing agreement for the development of a Cripto-1 mAB with leading Dutch
antibody development company Bioceros (see ASX announcement, 17 August 2010)." + "There is a large global market for mAB treatments. According to leading pharmaceutical industry
research group, GBI Pharmaceutical Research, the global mAB market was worth US$46.8 billion in
sales, in 2010."
“The global market for ovarian cancer therapeutics was valued at US$2.1b in 2007
and was estimated to have grown to US$3.6b1.”
I say no more..Potential is huge & PRR has more than one singal product..DYOR
announcement coming..., page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.015(3.70%) |
Mkt cap ! $570.1M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 40.8¢ | 39.0¢ | $1.074M | 2.720M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 73462 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 104768 | 20 |
View Market Depth
| Last trade - 14.44pm 02/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |